Join Ab Initio Pharma at DDL 2024: Shaping the Future of Inhaled Therapies
We are thrilled to announce our participation in the 35th Drug Delivery to the Lungs (DDL) Conference, taking place December 11–13, 2024, at the Edinburgh International Conference Centre. This prestigious event gathers global leaders in pulmonary and nasal drug delivery to explore cutting-edge innovations and advancements in the field.
As a Silver Sponsor and exhibitor, Ab Initio Pharma is proud to showcase our one-stop CDMO services that can take your drug from bench through to GMP manufacture at Booth #210. Stop by to learn how we’re advancing drug delivery solutions for small molecules, proteins, peptides, oligonucleotides, and RNA-based therapies.
Don’t miss our contributions to the program:
Listen to Chief Scientific Officer, Dr. Hui Xin Ong (YY), speak on "Enhancing the Intranasal Delivery of mRNA Therapeutics Using a Novel Thermosensitive Polymer." This presentation is part of Session 3: Gene Therapy and Biologics for the Lungs, scheduled for Wednesday, December 11, 2024, from 4:30 PM to 5:50 PM.
Read how we we’re revolutionising the development of inhaled biologics with our poster on inhaled oligonucleotides.
We’re excited to connect with industry experts and showcase how we’re revolutionising the development of inhaled therapies, including biologics. Let’s collaborate to push the boundaries of drug delivery technology!
#DDL2024 #InhaledBiologics #DrugDeliveryInnovation
